Filing Details

Accession Number:
0001062993-21-003864
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-27 19:30:17
Reporting Period:
2021-04-27
Accepted Time:
2021-04-27 19:30:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724979 Rain Therapeutics Inc. RAIN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-27 879,703 $0.00 879,703 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-04-27 1,107,316 $0.00 1,987,019 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-04-27 550,000 $17.00 2,537,019 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2021-04-27 949,992 $0.00 879,803 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2021-04-27 1,195,792 $0.00 1,107,316 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock are convertible at any time, at the holder's election. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock have no expiration date. Effective upon the closing of the Issuer's initial public offering of its common stock, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted to shares of the Issuer's common stock.
  2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.